Faron Pharmaceuticals Oy (HEL:FARON)
Finland · Delayed Price · Currency is EUR | Market Cap | 94.82M -65.7% |
| Revenue (ttm) | n/a |
| Net Income | -16.34M |
| EPS | -0.12 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 757,281 |
| Open | 0.4675 |
| Previous Close | 0.4655 |
| Day's Range | 0.4540 - 0.4710 |
| 52-Week Range | 0.4365 - 2.4550 |
| Beta | 1.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents... [Read more]
Financial Performance
Financial StatementsNews
Faron Pharmaceuticals Oy Earnings Call Transcript: H1 2026
Bexmarilimab shows strong efficacy and safety in HR-MDS, with a 45% complete remission rate and robust last-line results. EUR 40 million raised secures funding through key milestones in 2027, with a strengthened balance sheet and disciplined cost management.
Faron Pharmaceuticals Oy Quarterly report: H1 2026
Faron Pharmaceuticals Oy has published its H1 2026 quarterly earnings report on August 26, 2026.
Faron Pharmaceuticals Oy Slides: H1 2026
Faron Pharmaceuticals Oy has posted slides in relation to its H1 2026 quarterly earnings report, which was published on August 26, 2026.
Faron Pharmaceuticals share price targets 762% on bexmarilimab trial momentum
Faron Pharmaceuticals share price is trading at 39.5p, yet analysts have set an average 12-month price target of 340p, implying a gain of 762% if the consensus proves correct. One analyst sits even hi...
Faron Pharmaceuticals Oy Transcript: Status update
Bexmarilimab plus azacitidine shows high response rates and durable remissions in high-risk MDS, including TP53-mutated patients, with a favorable safety profile. The phase IIb BEXERA trial is set to launch soon, with strong investigator interest and key milestones expected this year.
Faron Pharmaceuticals Oy Press release: Status update
Faron Pharmaceuticals Oy issued a press release on June 15, 2026, disclosing material business information to investors.
Faron Pharmaceuticals Oy Transcript: Investor update
Bexmarilimab targets CLEC-1 on macrophages, showing strong efficacy and safety in high-risk MDS, with a 45% CR rate and extended survival. A €40 million fully committed rights offering will fund a pivotal phase IIb trial and multiple solid tumor studies, positioning the asset for major commercial and partnership opportunities.
Faron Pharmaceuticals Oy Slides: Investor update
Faron Pharmaceuticals Oy has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
Faron Pharmaceuticals Oy Earnings Call Transcript: H2 2025
Outstanding clinical results in high-risk MDS, improved financial position, and a robust pipeline set the stage for a pivotal phase 2b trial and expansion into new indications. Planned EUR 40 million rights offering aims to fund key milestones.
Faron Pharmaceuticals Oy Quarterly report: H2 2025
Faron Pharmaceuticals Oy has published its H2 2025 quarterly earnings report on March 4, 2026.
Faron Pharmaceuticals Oy Annual report: H2 2025
Faron Pharmaceuticals Oy has published its H2 2025 annual report on March 4, 2026.
Faron Pharmaceuticals Oy Slides: H2 2025
Faron Pharmaceuticals Oy has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 4, 2026.
Faron Pharmaceuticals Oy Transcript: Investor update
High and durable response rates in high-risk MDS have led to a revised, de-risked trial design using CR as the approval endpoint, supported by FDA guidance. Partnering interest is strong, with a new value inflection point expected from Phase II data in November.
Faron Pharmaceuticals Oy Slides: Investor update
Faron Pharmaceuticals Oy has posted slides in relation to its latest quarterly earnings report, which was published on February 11, 2026.
Faron Pharmaceuticals Oy Transcript: ESMO 2025 Conference
Bexmarilimab plus azacitidine demonstrated strong efficacy and safety in high-risk and HMA-failed MDS, with particularly high response rates in low blast count patients. A pivotal phase 2/3 trial is planned, and development is expanding into AML, solid tumors, and autoimmune indications.
Faron Pharmaceuticals Oy Press release: FY 2025
Faron Pharmaceuticals Oy issued a press release on October 23, 2025, disclosing material business information to investors.
Faron Pharmaceuticals Oy Slides: FY 2025
Faron Pharmaceuticals Oy has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 23, 2025.
Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data
At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Result...